Clari
ClariTrial
Built by Johnny Rice
Search
Explore
Companies
Targets
Safety
Pipeline
Competitive
Emerging
Map
Parsing your search query…
Explore
/
Vividion Therapeutics
Search
Status
Recruiting
Active
Not Yet
Completed
Terminated
Phase
Early Ph 1
Phase 1
Phase 2
Phase 3
Phase 4
N/A
4
results for
“Vividion Therapeutics”
NCT06804824
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Phase 1
Advanced Solid Tumors
VVD-159642
Sotorasib
Trametinib
Vividion Therapeutics, Inc.
220 participants
9 sites · United States, Australia
Completes Aug 2027
More detail
Compare
CT.gov
Full analysis →
NCT06004245
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Phase 1
Advanced Solid Tumors
Colorectal Cancer
VVD-133214
Pembrolizumab
Bevacizumab
Vividion Therapeutics, Inc.
280 participants
29 sites · United States, Australia, Belgium
Completes May 2027
More detail
Compare
CT.gov
Full analysis →
NCT05954312
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1
Advanced Solid Tumors
VVD-130037
Docetaxel
Paclitaxel
+1 more
Vividion Therapeutics, Inc.
290 participants
25 sites · United States, South Korea, Spain
Completes Aug 2030
More detail
Compare
CT.gov
Full analysis →
NCT06188208
Terminated
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Phase 1
Advanced Solid Tumors
Advanced Hematologic Tumors
VVD-130850
Pembrolizumab
Vividion Therapeutics, Inc.
132 participants
20 sites · United States, Australia, Spain
Completes Dec 2025
More detail
Compare
CT.gov
Full analysis →
Previous
1–4 of 4
Next